Josepmaria Argemi retweetledi

HIGHEST RANKED TRIALS for 2025
TOP 10 #cancerclinicaltrials in 2025 w/MOST Impact
1/ #DeLLphi304 @NEJM led by #Zeusofoncology @g_mountzios @HenryDunantGR : In relapsed SCLC post-platinum, BiTE DLL-3 Tarlatamab improved mOS vs. Chemo (13.6 vs 8.3 m, HR 0.60). PFS and in cancer-related dyspnea also improved.
nejm.org/doi/full/10.10…



English

























